Raloxifene
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Raloxifene: From Postmenopausal Osteoporosis to Duodenal Ulcer
One-Sentence Summary
Raloxifene is a selective estrogen receptor modulator (SERM) established for postmenopausal osteoporosis. The TxGNN model’s top-ranked prediction for this drug is Duodenal Ulcer, but currently no clinical trials and no literature support this direction — the evidence pack itself flags this as a likely knowledge-graph noise artifact rather than a genuine repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Postmenopausal osteoporosis / prevention of vertebral fractures (not present in EU license registry data — see Data Gap DG001; sourced from supporting literature in this pack) |
| Predicted New Indication | Duodenal Ulcer (disease) |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on information available in this evidence pack, Raloxifene is a nonsteroidal selective estrogen receptor modulator (SERM), and its efficacy in postmenopausal osteoporosis / prevention of non-traumatic vertebral fractures has been established in the literature associated with this dataset.
However, for the top-ranked predicted indication — duodenal ulcer — the evidence pack’s own mechanistic assessment concludes there is no known relationship between SERM pharmacology and duodenal ulcer pathophysiology (which is primarily driven by H. pylori infection and gastric acid secretion). The rationale explicitly characterizes this as a “graph noise-type prediction” from TxGNN, meaning the high similarity score likely reflects structural proximity in the knowledge graph rather than a biologically plausible therapeutic link. No supporting clinical or literature evidence exists to counter this assessment.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No marketing authorizations are recorded for this drug in the current dataset. Market status is listed as Not marketed (Not marketed), with 0 total licenses — this itself is flagged as a data gap requiring verification against the official EU/EMA registry (see DG001).
Safety Considerations
Please refer to the SmPC for safety information.
Note: This evidence pack marks TFDA/label warnings and contraindications (DG001, Blocking severity) as unresolved, and mechanism-of-action data (DG002, High severity) as unresolved. These gaps currently prevent progression to a full safety review (Stage S1).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (duodenal ulcer) has zero supporting clinical trials or literature (Evidence Level L5, Decision Stage S0), and the pack’s own mechanistic rationale identifies it as a likely spurious knowledge-graph prediction with no plausible pharmacological basis. Combined with a Blocking-severity gap in safety/label data, there is currently insufficient basis to advance this candidate.
To proceed, the following is needed:
- Resolve DG001: Obtain TFDA/EMA label warnings and contraindications (required before any Stage S1 safety evaluation)
- Resolve DG002: Retrieve confirmed mechanism of action via DrugBank API
- Verify EU marketing authorization status directly against EMA registry, as “0 licenses / not marketed” is inconsistent with Raloxifene’s known market history and should be confirmed rather than assumed accurate
- Conduct a targeted literature/clinical trial search specific to “duodenal ulcer” to confirm the absence of a genuine signal before closing this candidate
- If repurposing potential is still of interest, consider re-examining lower-ranked candidates with clearer mechanistic coherence (e.g., rank 8, pregnancy-associated osteoporosis, which reached L3/S1 but carries a conflicting teratogenicity contraindication) rather than pursuing the top-ranked but noise-flagged prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.